^
Association details:
| Biomarker: | CD70 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | CAT-248 (CD70 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1001 CAT-248 (engineered NK cells expressing CD70 CAR, IL15, and TGFβ DNR) demonstrates in vivo expansion, tumor infiltration, and durable regression of multiple CD70-expressing xenograft tumors
Published date:
11/04/2023
Excerpt:
CAT-248 infiltrates and durably regresses tumor xenografts expressing CD70 at high, medium or low antigen densities. CAT-248 has the potential to be a potent and durably effective allogeneic NK cell therapy for CD70 expressing solid tumors.
DOI:
10.1136/jitc-2023-SITC2023.1001
